Skip to main content
SpringerLink
Log in

Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb)

  • Published:
Journal of Materials Science: Materials in Medicine Aims and scope Submit manuscript

Abstract

Therapeutic aerosol bioengineering (TAB) of Mycobacterium tuberculosis (MTb) therapies using inhalable microparticles offers a unique opportunity to target drugs to the site of infection in the alveolar macrophages, thereby increasing dosing in the lungs and limiting systemic exposure to often toxic drugs. Previous work by us used sophisticated, high content analysis to design the optimal poly(lactide-co-glycolic) acid (PLGA) microparticle for delivery of drugs to alveolar macrophages. Herein, we applied this technology to three different anti-MTb drugs. These formulations were then tested for encapsulation efficiency, drug-release, in vitro killing against MTb and aerosol performance. Methods for encapsulating each of the drugs in the PLGA microparticles were successfully developed and found to be capable of controlling the release of the drug for up to 4 days. The efficacy of each of the encapsulated anti-MTb drugs was maintained and in some cases enhanced post-encapsulation. A method of processing these drug-loaded microparticles for inhalation using standard dry powder inhaler devices was successfully developed that enabled a very high respirable dose of the drug to be delivered from a simple dry powder inhaler device. Overall, TAB offers unique opportunities to more effectively treat MTb with many potential clinical and economic benefits resulting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Muttil P, Wang C, Hickey A. Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26(11):2401–16.

    Article  CAS  Google Scholar 

  2. Misra A, et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis. 2011;91(1):71–81.

    Article  CAS  Google Scholar 

  3. O’ Hara P, Hickey A. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterisation. Pharm Res. 2000;17(18):956–61.

    Google Scholar 

  4. Sung J, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009;26(8):1847–55.

    Article  CAS  Google Scholar 

  5. Pandey R, et al. Poly(dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003;52(6):981–6.

    Article  CAS  Google Scholar 

  6. Lawlor C, et al. The application of high-content analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages. Mol Pharm. 2011;8(4):1100–12.

    Article  CAS  Google Scholar 

  7. Hirota K, et al. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release. 2010;142(3):339–46.

    Article  CAS  Google Scholar 

  8. Suarez S, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48(3):431–4.

    Article  CAS  Google Scholar 

  9. Sharma R, et al. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res. 2001;18(10):1405–10.

    Article  CAS  Google Scholar 

  10. Yadav AB, Misra A. Enhancement of apoptosis of thp-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactercidal activity. Antimicrob Agents Chemother. 2007;51:3740–2. doi:10.1128/AAC.00925-07.

    Article  CAS  Google Scholar 

  11. Pillai O, Panchagnula R. Polymers in drug delivery. Curr Opin Chem Biol. 2001;5(4):447–51.

    Article  CAS  Google Scholar 

  12. Swai H, et al. Potential of treating tuberculosis with a polymeric nano-drug delivery system. J Control Release. 2008;132(3):e48.

    Article  CAS  Google Scholar 

  13. Murray CJ, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis. 1990;65(1):6–24.

    CAS  Google Scholar 

  14. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5–24.

    Article  CAS  Google Scholar 

  15. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209–27.

    Google Scholar 

  16. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1–2):1–19.

    Article  CAS  Google Scholar 

  17. Heyder J, et al. Deposition of particles in the human respiratory tract in the size range 0.005–15 [mu]m. J Aerosol Sci. 1986;17(5):811–25.

    Article  Google Scholar 

  18. Muttil P, et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 2007;32(2):140–50.

    Article  CAS  Google Scholar 

  19. McConville JT, et al. Use of a novel modified TSI for the evaluation of controlled-release aerosol formulations. I. Drug Dev Ind Pharm. 2000;26(11):1191–8.

    Article  CAS  Google Scholar 

  20. Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm. 1995;116(2):169–77.

    Article  CAS  Google Scholar 

  21. Dunbar C, Kataya A, Tiangbe T. Reducing bounce effects in the Andersen cascade impactor. Int J Pharm. 2005;301(1–2):25–32.

    Article  CAS  Google Scholar 

  22. Smyth H, Hickey A. Carriers in drug powder delivery: implications for inhalation system design. Am J Drug Deliv. 2005;3:117–32.

    Article  CAS  Google Scholar 

  23. Seville PC, et al. Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 2007;178(1):40–50.

    Article  CAS  Google Scholar 

  24. Chew NY, et al. Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci. 2005;94(10):2289–300.

    Article  CAS  Google Scholar 

  25. Daviskas E, et al. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J. 2008;31(4):765–72.

    Article  CAS  Google Scholar 

  26. Gray V, et al. The inhalation ad hoc advisory panel for the usp performance tests of inhalation dosage forms. Pharmacopeial Forum. 2008;34(4):1068–74.

    Google Scholar 

  27. Rabbani NR, Seville PC. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release. 2005;110(1):130–40.

    Article  CAS  Google Scholar 

  28. Jensen DMK, et al. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release. 2010;142(1):138–45.

    Article  Google Scholar 

  29. Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci. 1998;7(1):73–80.

    Article  CAS  Google Scholar 

  30. Learoyd TP, et al. Modified release of beclomethasone dipropionate from chitosan-based spray-dried respirable powders. Powder Technol. 2008;187(3):231–8.

    Article  CAS  Google Scholar 

  31. Hamishehkar H, et al. Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules. Powder Technol. 2010;201(3):289–95.

    Article  CAS  Google Scholar 

Download references

Acknowledgment

This study was funded by a Health Research Board Award(RP2006/152).

Author information

Authors and Affiliations

  1. School of Pharmacy, Royal College of Surgeons in Ireland, Dublin 2, Ireland

    C. Lawlor, B. Rice, P. Dillon, P. J. Gallagher & S.-A. Cryan

  2. Institute of Molecular Medicine, Trinity College Health Science Building, St. James’ Hospital, Dublin 8, Ireland

    C. Lawlor, M. P. O’Sullivan, S. O’Leary & J. Keane

  3. Department of Pharmaceutical Sciences, School of Pharmacy, Thomas Jefferson University, Edison Building, 130 South 9th Street, Philadelphia, PA, 19107-5233, USA

    S. Shoyele

Authors
  1. C. Lawlor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. P. O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Rice
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Dillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. J. Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. O’Leary
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Shoyele
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Keane
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S.-A. Cryan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S.-A. Cryan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lawlor, C., O’Sullivan, M.P., Rice, B. et al. Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb). J Mater Sci: Mater Med 23, 89–98 (2012). https://doi.org/10.1007/s10856-011-4511-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10856-011-4511-4

Keywords

Search

Navigation